Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC): A new approach for the treatment of human papillomavirus (HPV-induced tumors — Robert Snoeck (1995) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC): A new approach for the treatment of human papillomavirus (HPV-induced tumors
Shared by
De Clercq Erik
KU Leuven
(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC): A new approach for the treatment of human papillomavirus (HPV-induced tumors
Article
1995
en
Authors
+2 more
RS
Robert Snoeck
GA
Graciela Andreï
MR
Marc Van Ranst
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
1991
Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro
Johan Neyts
,
Robert Snoeck
,
Jan Balzarini
,
De Clercq Erik
Article
1994
(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC): successful treatment of a patient with disseminated esophageal and hypopharyngeal papillomatosis
Robert Snoeck
,
Eric Van Cutsem
,
Marc Van Ranst
,
Paul Rutgeerts
,
Ghislain Opdenakker
,
De Clercq Erik
Article
1995
Successful treatment of severe anogenital papillomavirus infections in AIDS patients with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine
Stéphane De Wit
,
Robert Snoeck
,
Martine Poncin
,
Marc Van Ranst
,
Graciela Andreï
,
De Clercq Erik
,
Nathan Clumeck
Article
1991
Lack of retinal toxicity of the anti-CMV drug (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC)
D.R. Dolnack
,
D. Munguai
,
G Bergeron-Lynn
,
Clayton A. Wiley
,
De Clercq Erik
,
Claude Boscher
,
James D. Connor
,
W.R. Freeman
Article
1991
Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [HPMPC] against intraperitoneal and intracerebral murine cytomegalovirus infections
Johan Neyts
,
Jan Balzarini
,
De Clercq Erik
Discussion(0)
No comments yet. Be the first to comment.